Clinical Trials 20 February 2026 - 1 June 2026

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN
····

Design Therapeutics Drops Ahead of Jefferies, Trial Remains in Focus for DSGN

Design Therapeutics shares slid on Tuesday afternoon, dropping 24 cents to $10.20 in a broader biotech selloff. The Carlsbad, California-based firm was off roughly 2.3%. The SPDR S&P Biotech ETF lost about 4.0%, and the iShares Nasdaq Biotechnology ETF slipped about 3.0%. Design shares are in focus again since there’s been no new trial data update. The most recent post on Design’s investor page is still the May 28 Jefferies conference notice. Management is slated for a fireside chat in New York on June 4 at 1:25 p.m. EDT.
June 2, 2026
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data
····

Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data

Aclaris Therapeutics dropped 12.5 cents to $4.43 late Monday, underperforming broad biotech indexes after little recent news from the drugmaker. The SPDR S&P Biotech ETF lost 1.9%. The iShares Nasdaq Biotechnology ETF slid 1.4%. An ETF is a basket of securities trading like a single stock. Aclaris’ next shot with investors is coming up. The Wayne, Pennsylvania company said CEO Dr. Neal Walker and other executives will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday at 2 p.m. ET. Its investor-relations site hasn’t posted anything newer than the May 28 release.
June 1, 2026
Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus
····

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares are on a four-day losing streak on Nasdaq as the new week begins. Investors are watching for a Sunday evening cancer conference event that could be key for the stock’s direction. Legend Biotech shares ended Friday at $27.16, losing 3.89% on the session. The stock is now trading about 7.5% lower than the previous Friday’s close of $29.37. U.S. markets saw a shortened week due to the Memorial Day holiday. Nasdaq is closed Sundays and trades Monday to Friday, 9:30 a.m. to 4 p.m. ET.
May 31, 2026
GH Research Stock Moves as Market Eyes Data in Holiday Week
····

GH Research Stock Moves as Market Eyes Data in Holiday Week

GH Research PLC finished Friday’s session up 1.6% at $22.12 and then ticked higher to $22.35 after hours. The Dublin biotech comes onto the radar for the upcoming holiday week, with new depression-drug data expected at conferences. The stock trades on Nasdaq. U.S. equity markets are closed for the weekend, and Nasdaq will stay shut on Monday, May 25, for Memorial Day. That means the next regular trading session lands as GH Research starts to present data at the American Society of Clinical Psychopharmacology meeting in Miami, set for May 26-29.
May 23, 2026
Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing
···

Xenon’s epilepsy drug posts strong Phase 3 data; XENE shares jump ahead of U.S. filing

Xenon Pharmaceuticals Inc reported Monday that its experimental epilepsy drug azetukalner reduced monthly focal onset seizures in a late-stage study, sparking a jump of over 40% in the stock before the bell. William Blair’s Myles Minter, in a note to clients, described the results as “unprecedented.” Xenon is feeling the heat as it waits to see if azetukalner can deliver enough for an approval push this year. That window is now off the table: the company says it’s aiming to file its New Drug Application in the third quarter of 2026.
March 9, 2026
Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
····

Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3

CORAL GABLES, Fla., March 9, 2026, 09:04 EDT Relmada Therapeutics plans to pull in roughly $160 million through a private placement, the company said Monday, after releasing year-long mid-stage trial data backing a move into late-stage development for NDV-01, its investigational bladder cancer drug. The round, oversubscribed and set at $4.75 per share, is expected to close around March 11.
March 9, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

NEW YORK, Feb 20, 2026, 16:53 EST — After-hours Grail plunged roughly 50% to $50.21 after hours on Friday, following news that its key UK trial for the Galleri cancer blood test failed to hit the main endpoint. TD Cowen’s Dan Brennan said Grail should address the mixed results with “proactive, transparent and deliberate” communication about the next steps.
February 20, 2026